PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 141 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2019. The put-call ratio across all filers is 0.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $139,188 | -45.4% | 52,923 | -26.8% | 0.00% | – |
| Q2 2023 | $255,106 | +12.5% | 72,268 | -1.5% | 0.00% | – |
| Q1 2023 | $226,691 | -7.6% | 73,363 | +26.5% | 0.00% | – |
| Q4 2022 | $245,353 | +245.6% | 58,003 | +93.1% | 0.00% | – |
| Q3 2022 | $71,000 | -22.0% | 30,033 | -6.3% | 0.00% | – |
| Q2 2022 | $91,000 | -72.6% | 32,052 | -72.2% | 0.00% | – |
| Q1 2022 | $332,000 | -6.2% | 115,396 | -0.6% | 0.00% | – |
| Q4 2021 | $354,000 | -57.8% | 116,096 | -3.0% | 0.00% | – |
| Q3 2021 | $839,000 | -18.9% | 119,681 | +6.1% | 0.00% | – |
| Q2 2021 | $1,035,000 | -21.6% | 112,768 | -17.0% | 0.00% | – |
| Q1 2021 | $1,320,000 | -8.6% | 135,805 | -3.5% | 0.00% | – |
| Q4 2020 | $1,444,000 | -3.9% | 140,734 | -5.5% | 0.00% | – |
| Q3 2020 | $1,502,000 | -3.7% | 148,931 | -0.4% | 0.00% | – |
| Q2 2020 | $1,560,000 | +8.3% | 149,550 | -12.3% | 0.00% | – |
| Q1 2020 | $1,440,000 | -5.1% | 170,597 | -1.6% | 0.00% | – |
| Q4 2019 | $1,518,000 | -16.1% | 173,457 | +3.2% | 0.00% | – |
| Q3 2019 | $1,809,000 | -10.1% | 168,071 | +6.1% | 0.00% | -100.0% |
| Q2 2019 | $2,013,000 | -71.0% | 158,406 | -11.4% | 0.00% | -50.0% |
| Q1 2019 | $6,933,000 | +107.7% | 178,709 | +9.0% | 0.00% | +100.0% |
| Q4 2018 | $3,338,000 | -61.3% | 164,016 | -12.9% | 0.00% | -50.0% |
| Q3 2018 | $8,632,000 | -19.9% | 188,301 | +3.4% | 0.00% | -33.3% |
| Q2 2018 | $10,775,000 | -13.4% | 182,186 | -0.4% | 0.00% | 0.0% |
| Q1 2018 | $12,445,000 | -28.7% | 182,888 | +3.6% | 0.00% | -40.0% |
| Q4 2017 | $17,443,000 | -20.1% | 176,466 | -3.2% | 0.01% | -16.7% |
| Q3 2017 | $21,832,000 | +83.3% | 182,298 | +33.8% | 0.01% | +100.0% |
| Q2 2017 | $11,912,000 | +138.5% | 136,297 | +1.5% | 0.00% | +200.0% |
| Q1 2017 | $4,994,000 | +3.1% | 134,225 | -14.9% | 0.00% | 0.0% |
| Q4 2016 | $4,844,000 | -54.4% | 157,786 | -0.4% | 0.00% | -66.7% |
| Q3 2016 | $10,623,000 | +218.7% | 158,443 | +41.6% | 0.00% | +200.0% |
| Q2 2016 | $3,333,000 | +6.6% | 111,918 | +5.1% | 0.00% | 0.0% |
| Q1 2016 | $3,128,000 | -61.2% | 106,495 | +3.5% | 0.00% | -50.0% |
| Q4 2015 | $8,063,000 | -8.3% | 102,862 | -11.8% | 0.00% | -33.3% |
| Q3 2015 | $8,792,000 | -26.5% | 116,662 | +13.8% | 0.00% | 0.0% |
| Q2 2015 | $11,968,000 | -62.4% | 102,511 | -23.9% | 0.00% | -62.5% |
| Q1 2015 | $31,799,000 | +36.4% | 134,677 | +9.3% | 0.01% | +33.3% |
| Q4 2014 | $23,321,000 | -23.2% | 123,217 | -3.2% | 0.01% | -25.0% |
| Q3 2014 | $30,363,000 | +114.1% | 127,267 | -40.8% | 0.01% | +300.0% |
| Q2 2014 | $14,184,000 | +13.7% | 214,900 | +79.3% | 0.00% | -33.3% |
| Q1 2014 | $12,479,000 | +11.8% | 119,837 | +11.1% | 0.00% | 0.0% |
| Q4 2013 | $11,166,000 | -52.2% | 107,849 | -75.2% | 0.00% | -25.0% |
| Q3 2013 | $23,376,000 | +105.3% | 435,624 | +69.7% | 0.00% | 0.0% |
| Q2 2013 | $11,387,000 | – | 256,646 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 1,417,000 | $18,010,000 | 2.24% |
| Palo Alto Investors LP | 1,405,680 | $17,866,000 | 0.87% |
| PFM Health Sciences, LP | 2,838,376 | $36,076,000 | 0.68% |
| TANG CAPITAL MANAGEMENT LLC | 349,400 | $4,441,000 | 0.60% |
| Capital Impact Advisors, LLC | 127,029 | $1,615,000 | 0.59% |
| Leap Investments LP | 29,100 | $370,000 | 0.50% |
| Spark Investment Management LLC | 454,300 | $5,774,000 | 0.40% |
| Partner Investment Management, L.P. | 27,567 | $350,000 | 0.37% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 262,945 | $3,342,000 | 0.26% |
| Rock Springs Capital Management LP | 534,400 | $6,792,000 | 0.25% |